Coverage
-
January 10, 2017
A California judge Tuesday dismissed a decade-old action claiming Amgen Inc.'s board caused more than $1 billion in damages by overseeing an off-label drug marketing scheme, saying the shareholder failed to make a demand on the officials to instigate litigation before filing her suit.
2 other articles on this case.
View all »